摘要
射血分数保留心力衰竭(HFpEF)是近年来备受重视的心力衰竭类型,患病率高,并有逐年增加的趋势,预后差。HFpEF的发病机制涉及多个方面,包括左心室舒张功能不全、左心室收缩功能异常、肺动脉高压、右心室功能障碍、内皮功能障碍以及炎症、肥胖、胰岛素抵抗和衰老等,特别是系统性炎症发挥重要作用。近年来,HFpEF的治疗有了新的方法,沙库巴曲缬沙坦在临床试验中显示了治疗的有效性和安全性。文章系统回顾了HFpEF的临床流行病学特征及发病机制,并根据近期临床研究,全面概述HFpEF治疗的最新进展。
Heart failure with preserved ejection fraction(HFpEF)is a common and important type of heart failure with a high prevalence and worse prognosis,and is increasing year by year. The pathogenesis of HFpEF is complex and involves many aspects,including left ventricular diastolic dysfunction and systolic dysfunction,pulmonary artery hypertension and right ventricular systolic dysfunction,endothelial dysfunction and inflammation,obesity,insulin resistance and aging,in particular,systematic inflammation plays an important role. There is a new treatment for HFpEF. Recent clinical trials have shown that sacubitrtil/valsartan is effective and safe in the treatment of HFpEF. This paper reviews the clinical epidemic features and latest understanding of the pathogenesis of HFpEF,and the latest progress in the treatment of HFpEF.
作者
周京敏
李福海
ZHOU Jing-min;LI Fu-hai(Department of Cardiology,Zhongshan Hospital,Fudan University,shanghai 200032,China)
出处
《中国实用内科杂志》
CAS
CSCD
北大核心
2020年第12期986-989,共4页
Chinese Journal of Practical Internal Medicine
基金
国家重点研发计划(2018YFE003000)
国家自然科学基金面上项目(81873123)。
关键词
射血分数保留心力衰竭
发病机制
治疗
heart failure with preserved ejection fraction
pathogenesis
treatment
